Obinutuzumab treatment for antineutrophil cytoplasmic antibody-associated vasculitis [PDF]
Frontiers in ImmunologyBackgroundAnti-CD20 therapy with rituximab serves as the cornerstone of both induction and maintenance treatment for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Chen Ye +26 more
doaj +2 more sources
Does baseline proteinuria affect the efficacy of obinutuzumab in patients with primary membranous nephropathy and minimal change disease? a single-center retrospective study [PDF]
Frontiers in PharmacologyBackgroundPrimary membranous nephropathy (PMN) and minimal change disease (MCD) are common causes of nephrotic syndrome in adults and represent the two diseases in which anti-CD20 monoclonal antibodies are most widely used.
Xueting Li, Yinghui Zhang, Ben Ke
doaj +2 more sources
Pirtobrutinib Monotherapy for First-Line Chronic Lymphocytic Leukemia: A Non-Anchored Indirect Comparison Using Reconstructed Patient-Level Data [PDF]
Hematology ReportsBackground: Pirtobrutinib has recently emerged as a promising first-line treatment option for chronic lymphocytic leukemia (CLL). Unlike currently established regimens, which are generally based on doublet combinations, pirtobrutinib can be administered ...
Andrea Messori +3 more
doaj +2 more sources
Obinutuzumab alone may be an effective option for adult minimal change disease: a single-center retrospective observational study [PDF]
BMC NephrologyBackground Obinutuzumab is a novel glycoengineered type II anti-CD20 monoclonal antibody with more potent and sustained B-cell depletion than rituximab.
Qiong Bai +3 more
doaj +2 more sources
Oncology and TherapyThrombocytopenia has been reported more frequently with obinutuzumab in clinical trials where it was directly compared with rituximab. However, more significant than the frequency, a unique form of severe thrombocytopenia manifesting very early after the
Selin Kucukyurt +2 more
exaly +2 more sources
Obinutuzumab versus rituximab in refractory membranous nephropathy: a single-center retrospective cohort study [PDF]
BMC NephrologyBackground Refractory membranous nephropathy (MN) remains challenging. We aim to compare the efficacy and safety of obinutuzumab versus rituximab in adults with refractory or relapsing MN, using a retrospective, single-center study design.
Wenhui Lei +4 more
doaj +2 more sources
Obinutuzumab for refractory minimal change disease in obese patients: a case series [PDF]
Frontiers in MedicineMinimal change disease (MCD) is a common cause of nephrotic syndrome in adults. Rituximab, a type I anti-CD20 antibody, is effective in many cases, but up to 40% of patients show an insufficient or transient response.
Dandan Xue +4 more
doaj +2 more sources
Obinutuzumab versus rituximab-based chemotherapy in high-tumor burden indolent B-cell lymphoma: a real-world comparative study [PDF]
Frontiers in ImmunologyBackgroundPatients with previously untreated follicular lymphoma (FL) or marginal zone lymphoma (MZL) with high-tumor burden represent a subset with unfavorable prognosis.
Xin Wan +6 more
doaj +2 more sources
Kidney International ReportsIntroduction: Although rituximab has significantly improved outcomes for patients with membranous nephropathy, response to treatment is not universal and drug resistance can occur.
Kevin Zorzi +2 more
exaly +3 more sources
Efficacy and safety of obinutuzumab in patients with primary membranous nephropathy: a focus on refractory and rituximab-resistant patients [PDF]
Frontiers in ImmunologyBackgroundThere has been an annual rise in the incidence of primary membranous nephropathy (PMN), a common pathological type of nephrotic syndrome (NS). Obinutuzumab is a humanised, glycosylated, type II anti-CD20 monoclonal antibody.
Qi Gao +5 more
doaj +2 more sources